IM Cannabis (NASDAQ:IMCC) Releases Earnings Results, Misses Estimates By $0.95 EPS

IM Cannabis (NASDAQ:IMCC) announced its quarterly earnings data on Monday. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.95), Zacks reports. IM Cannabis had a negative net margin of 9.47% and a negative return on equity of 134.35%.

IM Cannabis Stock Performance

NASDAQ IMCC opened at $0.41 on Tuesday. The firm has a market capitalization of $2.40 million, a P/E ratio of -0.52 and a beta of 2.17. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 0.25. The firm’s fifty day moving average price is $0.94 and its two-hundred day moving average price is $1.39. IM Cannabis has a 1 year low of $0.30 and a 1 year high of $7.12.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IM Cannabis in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, IM Cannabis presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IM Cannabis stock. DRW Securities LLC bought a new stake in IM Cannabis Corp. (NASDAQ:IMCC) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 23,060 shares of the company’s stock, valued at approximately $32,000. DRW Securities LLC owned 0.39% of IM Cannabis as of its most recent filing with the SEC. Institutional investors own 7.68% of the company’s stock.

About IM Cannabis

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.